新发癫痫发作与SARS-CoV-2疫苗的关联:随机临床试验的系统综述与Meta分析
该系统综述与Meta分析纳入6项随机临床试验,比较SARS-CoV-2疫苗组与安慰剂组新发癫痫发作的发生率。接种后28天随访中,疫苗组与安慰剂组新发癫痫发作风险无统计学显著差异(OR 2.70,95%CI 0.76-9.57,P=.12)。在整个盲态期(中位随访超过43天)同样无显著差异(OR 2.31,95%CI 0.86-6.23,P=.10)。
要点
- 6项随机临床试验的Meta分析显示,SARS-CoV-2疫苗组与安慰剂组新发癫痫发作风险无统计学显著差异。
- 接种后28天随访:疫苗组9例(0.014%)vs 安慰剂组1例(0.002%),OR 2.70(95%CI 0.76-9.57),P=.12。
- 盲态期随访(中位超过43天):疫苗组13/43724例(0.03%)vs 安慰剂组5/40612例(0.012%),OR 2.31(95%CI 0.86-6.23),P=.10。
核心结论
- 该系统综述与Meta分析显示,疫苗接种者与安慰剂接受者之间新发癫痫发作的发生率无统计学显著差异。
研究设计与样本
- 系统综述与Meta分析,纳入6项报告SARS-CoV-2疫苗接种后癫痫发作发生率的随机临床试验。
- 检索MEDLINE(通过PubMed)、Web of Science、Scopus、Cochrane Library、Google Scholar、综述出版物、社论、致编辑信和会议论文,以及纳入研究的参考文献,时间从2019年12月至2023年7月7日。
- 采用Mantel-Haenszel方法,使用随机效应和固定效应模型;使用Cochrane随机临床试验偏倚风险评估工具评估研究偏倚风险。
主要发现
- 接种后28天随访:疫苗组63521例中9例(0.014%)发生新发癫痫发作,安慰剂组54919例中1例(0.002%),OR 2.70(95%CI 0.76-9.57),P=.12,I²=0%,τ²=0,Cochran Q P=.74。
- 整个盲态期随访(中位超过43天):疫苗组43724例中13例(0.03%)发生新发癫痫发作,安慰剂组40612例中5例(0.012%),OR 2.31(95%CI 0.86-6.23),P=.10,I²=0%,τ²=0,Cochran Q P=.95。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Seizures have been reported as an adverse effect of the SARS-CoV-2 vaccine. However, no study has answered the question of whether there is any association between seizures in the general population and COVID-19 vaccination. OBJECTIVE: To evaluate the seizure incidence among SARS-CoV-2 vaccine recipients compared with those who received a placebo. DATA SOURCES: A systematic search of MEDLINE (via PubMed), Web of Science, Scopus, Cochrane Library, Google Scholar, review publications, editorials, letters to editors, and conference papers, along with the references of the included studies from December 2019 to July 7, 2023. STUDY SELECTION: Randomized clinical trials (RCTs) reporting seizure incidence with SARS-CoV-2 vaccination were included. DATA EXTRACTION AND SYNTHESIS: This study is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses framework and used the Mantel-Haenszel method with random- and common-effect models. The risk of bias of the studies was assessed using the Cochrane assessment tool for RCTs. MAIN OUTCOMES AND MEASURES: The outcome of interest was new-onset seizure incidence proportion compared among (1) SARS-CoV-2 vaccine recipients and (2) placebo recipients. RESULTS: Six RCTs were included in the study. Results of the pooled analysis comparing the incidence of new-onset seizure between the 63 521 vaccine and 54 919 placebo recipients in the 28-day follow-up after vaccine/placebo injection showed no statistically significant difference between the 2 groups (9 events [0.014%] in vaccine and 1 event [0.002%] in placebo recipients; odds ratio [OR], 2.70; 95% CI, 0.76-9.57; P = .12; I2 = 0%, τ2 = 0, Cochran Q P = .74). Likewise, in the entire blinded-phase period after injection, with a median of more than 43 days, no significant difference was identified between the vaccine and placebo groups regarding incident new-onset seizure (13/43 724 events [0.03%] in vaccine and 5/40 612 [0.012%] in placebo recipients; OR, 2.31; 95% CI, 0.86-6.23, P = .10, I2 = 0%, τ2 = 0, Cochran Q P = .95). CONCLUSIONS AND RELEVANCE: According to this systematic review and meta-analysis, there was no statistically significant difference in the risk of new-onset seizure incidence between vaccinated individuals and placebo recipients.
引用
- Rafati A, Jameie M, Amanollahi M, et al. Association of New-Onset Seizures With SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. JAMA Neurol. 2024. PMID: 38683573. doi:10.1001/jamaneurol.2024.0967
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。